- Leukemia, Acute Myeloid (AML)
|
Mark Chao |
Forty Seven Inc. |
Phase 1 |
Active, not recruiting |
258 |
|
|
Michael Pulsipher |
Children's Hospital of Los Angeles |
Phase 1/2 |
Active, not recruiting |
60 |
|
- Leukemia, Acute Myeloid (AML)
|
Colleen Delaney |
Nohla Therapeutics Inc |
Phase 2 |
Closed |
146 |
|
|
Matthew Spear |
Poseida Therapeutics, Inc. |
Phase 1 |
Closed |
105 |
|
|
Edward Kavalerchik |
Angiocrine Bioscience, Inc. |
Phase 1 |
Completed |
10 |
|
|
Thomas Kipps |
University of California, San Diego |
Phase 1 |
Completed |
26 |
|
|
Irving Weissman |
Stanford University |
Phase 1 |
Completed |
88 |
|
|
Edward Kavalerchik |
Angiocrine Bioscience, Inc. |
Phase 1 |
Completed |
42 |
|
|
Thomas Kipps |
University of California, San Diego |
Phase 1/2 |
Recruiting |
138 |
|
|
Mehrdad Abedi |
University of California, Davis |
Phase 1/2 |
Recruiting |
18 |
|
|
David Miklos |
Stanford University |
Phase 1 |
Recruiting |
60 |
|
- Leukemia, Acute Myeloid (AML)
|
Joseph Woodard |
Immune-Onc Therapeutics |
Phase 1 |
Recruiting |
119 |
|
- B cell cancers
- Leukemia
- Leukemia, Acute Myeloid (AML)
|
Maria Grazia Roncarolo |
Stanford University |
Phase 1 |
Recruiting |
22 |
|